Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Antispasmodics Drugs Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The antispasmodics drugs market has seen significant expansion in recent years. It is projected to grow from $14.93 billion in 2025 to $16.34 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.5%. This growth during the historic period can be ascribed to a rising incidence of IBS and stomach cramps, the development of hospital pharmacy infrastructure, the increasing adoption of oral antispasmodic tablets, greater awareness about gastrointestinal health, and improvements in drug formulation technologies.
The antispasmodics drugs market is projected to experience robust expansion over the coming years, reaching a valuation of $23.47 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 9.5%. This anticipated growth during the forecast period is propelled by several factors, including breakthroughs in precision medicine, the creation of injectable and liquid antispasmodic formulations, the widening reach of online pharmacy platforms, an expanding elderly and young patient demographic, and the incorporation of digital health monitoring systems. Key developments expected within this period encompass individualized antispasmodic treatments, sophisticated drug delivery methods, an escalation in gastrointestinal conditions, increased adoption of homecare medications, and an intensified concentration on both pediatric and geriatric patient groups.
Get A Free Sample Report With In-Depth Market Insights:
Antispasmodics Drugs Market Demand Drivers Opening New Revenue Streams
The antispasmodic drug market is expected to grow, propelled by an increasing elderly population. Individuals aged 65 years and older, considered elderly, face numerous physical and psychological health issues. Antispasmodic drugs are beneficial for these populations in managing symptoms such as muscle spasms or cramping, and can also be used for conditions like irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramping. For instance, according to the UK Parliament’s House of Commons Library in July 2024, the UK had 12.7 million people aged 65 or older in 2022. This figure is projected to reach 22.1 million by 2072, making up 27% of the population, thus driving the antispasmodic drug market.
Antispasmodics Drugs Market Segmentation And Category Overview
The antispasmodics drugs market covered in this report is segmented –
1) By Drug: Dicyclomine Hydrochloride, Loperamide Hydrochloride, Other Drugs
2) By Indication: Irritable Bowel Syndrome, Stomach Cramps, Other Indications
3) By Route Of Administration: Oral, Parenteral, Other Modes Of Administrations
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Dicyclomine Hydrochloride: Oral Tablets, Injectable Formulations
2) By Loperamide Hydrochloride: Oral Tablets, Liquid Formulations
3) By Other Drugs: Hyoscine Butylbromide (Scopolamine), Peppermint Oil, Atropine, Other Antispasmodics
Antispasmodics Drugs Market Trends Powering Strategic Industry Growth
Major companies operating within the antispasmodics drugs market are unveiling new products to maintain their market presence. An illustration of this occurred in January 2023, when Lupin Limited, an Indian pharmaceutical company, launched Fesoterodine Fumarate. This product had received approval from the Food and Drug Administration (FDA), a US federal government agency. Fesoterodine fumarate serves as a generic antispasmodic medication prescribed for certain bladder issues, such as overactive bladder and neurogenic detrusor overactivity. Categorized as an antispasmodic, it operates by relaxing the muscles of the bladder and is accessible as extended-release tablets.
Antispasmodics Drugs Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the antispasmodics drugs market are Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Pfizer Inc., Shanghai Fosun Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Akorn Inc., Aurobindo Pharma Limited, Lannett Company Inc., Nexus Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Blue Cross Laboratories Pvt. Ltd., Dr. Reddy’s Laboratories Ltd., Lexicare Pharma Pvt. Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Wellona Pharma Private Limited, SunGen Pharma LLC, GlaxoSmithKline plc, Novartis AG, Sanofi SA, AstraZeneca plc, Merck & Co. Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Ltd.
View The Full Antispasmodics Drugs Market Report:
Antispasmodics Drugs Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the antispasmodics drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the antispasmodics drugs market report during the forecast period. The regions covered in the antispasmodics drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model